@prefix jvr: . @prefix skos: . @prefix mesh: . @prefix dc: . @prefix xsd: . @prefix owl: . jvr:-BT300B3G-Q skos:prefLabel "cerebrospinal fluid (Qualifier)"@en, "liquide cérébrospinal (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-L6C0XPHT-4 skos:prefLabel "métabolisme (Qualificatif)"@fr, "metabolism (Qualifier)"@en ; a mesh:Qualifier, skos:Concept . jvr:-SGFM85SF-Z skos:prefLabel "Cytochrome P-450 CYP1A2 Inducers"@en, "Inducteurs du cytochrome P-450 CYP1A2"@fr ; a mesh:Descriptor, skos:Concept . jvr:-XV06LPML-W skos:prefLabel "urine (Qualifier)"@en, "urine (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-SLLN8F4V-8 skos:prefLabel "Anticonvulsants"@en, "Anticonvulsivants"@fr ; a mesh:Descriptor, skos:Concept . jvr:-Q3979798-W skos:prefLabel "analysis (Qualifier)"@en, "analyse (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-H7K65Q8S-Z skos:prefLabel "radiation effects (Qualifier)"@en, "effets des radiations (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-TJHVZCRZ-0 skos:prefLabel "administration et posologie (Qualificatif)"@fr, "administration & dosage (Qualifier)"@en ; a mesh:Qualifier, skos:Concept . jvr:-G30ZJ446-J skos:prefLabel "toxicity (Qualifier)"@en, "toxicité (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-NFTHND7Q-8 skos:prefLabel "intoxication (Qualificatif)"@fr, "poisoning (Qualifier)"@en ; a mesh:Qualifier, skos:Concept . jvr:-FWD2BGQ0-9 skos:prefLabel "usage thérapeutique (Qualificatif)"@fr, "therapeutic use (Qualifier)"@en ; a mesh:Qualifier, skos:Concept . jvr:-THHNVC7V-3 skos:prefLabel "synthèse chimique (Qualificatif)"@fr, "chemical synthesis (Qualifier)"@en ; a mesh:Qualifier, skos:Concept . jvr:-R0ZCQ8X6-J skos:prefLabel "agonistes (Qualificatif)"@fr, "agonists (Qualifier)"@en ; a mesh:Qualifier, skos:Concept . jvr:-S0CS1X5R-5 skos:prefLabel "immunology (Qualifier)"@en, "immunologie (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-M63HSDM7-1 skos:prefLabel "antagonists & inhibitors (Qualifier)"@en, "antagonistes et inhibiteurs (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-HQRFT0C6-B skos:prefLabel "isolement et purification (Qualificatif)"@fr, "isolation & purification (Qualifier)"@en ; a mesh:Qualifier, skos:Concept . jvr:-NB0XHT3S-N skos:prefLabel "adverse effects (Qualifier)"@en, "effets indésirables (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-W6SQV79N-S skos:prefLabel "classification (Qualifier)"@en, "classification (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-CB30NGKB-3 skos:prefLabel "economics (Qualifier)"@en, "économie (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-G4R176S9-J skos:prefLabel "analogs & derivatives (Qualifier)"@en, "analogues et dérivés (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr: a skos:ConceptScheme . jvr:-SBNWSM1T-R skos:prefLabel "history (Qualifier)"@en, "histoire (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-VNL7T8XW-F skos:prefLabel "Hydantoïnes"@fr, "Hydantoins"@en ; a mesh:Descriptor, skos:Concept ; skos:narrower jvr:-NRK4Q4CH-G . jvr:-NRK4Q4CH-G mesh:allowableQualifier jvr:-G30ZJ446-J, jvr:-NKM836P1-M, jvr:-NB0XHT3S-N, jvr:-WK5F724J-1, jvr:-BT300B3G-Q, jvr:-SBNWSM1T-R, jvr:-M63HSDM7-1, jvr:-D0F21513-5, jvr:-R0ZCQ8X6-J, jvr:-H7K65Q8S-Z, jvr:-NHL3D2X0-S, jvr:-R3QWLHRG-V, jvr:-T9HQD7ST-J, jvr:-HQRFT0C6-B, jvr:-CB30NGKB-3, jvr:-W6SQV79N-S, jvr:-NFTHND7Q-8, jvr:-FWD2BGQ0-9, jvr:-L6C0XPHT-4, jvr:-S0CS1X5R-5, jvr:-XV06LPML-W, jvr:-THHNVC7V-3, jvr:-Q3979798-W, jvr:-TJHVZCRZ-0, jvr:-G4R176S9-J ; skos:altLabel "4182431BJH"@fr, "4182431BJH"@en, "5,5-Diphenylhydantoin"@en, "2,4-Imidazolidinedione, 5,5-diphenyl-"@fr, "2,4-Imidazolidinedione, 5,5-diphenyl-"@en, "5,5-diphenylimidazolidine-2,4-dione"@en, "Fenitoin"@en, "6158TKW0C5"@fr, "6158TKW0C5"@en, "Diphenylhydantoin"@en, "57-41-0 (Phenytoin)"@en, "57-41-0 (Phenytoin)"@fr ; skos:definition "An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs."@en ; dc:modified "2021-07-01"^^xsd:date ; mesh:pharmacologicalAction jvr:-SLLN8F4V-8, jvr:-SGFM85SF-Z, jvr:-M8GPSGF8-B ; skos:hiddenLabel "Epamin"@en, "Phénytoïne de sodium"@fr, "Dilantin"@en, "Epanutin"@en, "Dihydan"@en, "Phenhydan"@en, "Hydantol"@en, "Antisacer"@en, "Phenytoin Sodium"@en, "Sodium Diphenylhydantoinate"@en, "Difenin"@en, "Phénytoïne sodique"@fr ; a skos:Concept, mesh:Descriptor ; skos:prefLabel "Phenytoin"@en, "Phénytoïne"@fr ; dc:created "1999-01-01"^^xsd:date ; owl:sameAs ; skos:inScheme jvr: ; dc:established "1966-01-01"^^xsd:date ; skos:broader jvr:-VNL7T8XW-F . jvr:-D0F21513-5 skos:prefLabel "chemistry (Qualifier)"@en, "composition chimique (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-R3QWLHRG-V skos:prefLabel "standards (Qualifier)"@en, "normes (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-NHL3D2X0-S skos:prefLabel "sang (Qualificatif)"@fr, "blood (Qualifier)"@en ; a mesh:Qualifier, skos:Concept . jvr:-T9HQD7ST-J skos:prefLabel "ressources et distribution (Qualificatif)"@fr, "supply & distribution (Qualifier)"@en ; a mesh:Qualifier, skos:Concept . jvr:-M8GPSGF8-B skos:prefLabel "Voltage-Gated Sodium Channel Blockers"@en, "Bloqueurs de canaux sodiques voltage-dépendants"@fr ; a mesh:Descriptor, skos:Concept . jvr:-NKM836P1-M skos:prefLabel "pharmacology (Qualifier)"@en, "pharmacologie (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept . jvr:-WK5F724J-1 skos:prefLabel "pharmacokinetics (Qualifier)"@en, "pharmacocinétique (Qualificatif)"@fr ; a mesh:Qualifier, skos:Concept .